ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
IPO Year: 2018
Exchange: NASDAQ
Website: aslanpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2021 | $8.00 | Buy | Jefferies |
New translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrationsLeading respiratory experts, Ramaswamy Krishnan, PhD, and Reynold Panettieri, MD, appointed as scientific advisors to provide strategic counsel on eblasakimab's differentiation for future clinical development in COPD SAN MATEO, Calif. and SINGAPORE, March 06, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (NASDAQ:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of p
- Dermatologist with over twenty years of experience in senior biopharma roles in the US and Europe, including positions at Almirall, Allergan and Novartis- Strengthens leadership team as eblasakimab (also known as ASLAN004) moves into late-stage trials MENLO PARK, Calif. and SINGAPORE, March 15, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Alex Kaoukhov, MD, as Chief Medical Officer based in ASLAN's US office, effective immediately. Alex was most recently Head of Clinical Development, Senior Vice President
MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials, including the global oversight, expansion and engagement of patients for trials related to the clinical development of ASLAN004 and ASLAN003. IQVIA Biotech will provide pati
MENLO PARK, Calif. and SINGAPORE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointments of Dr Melinda Jennifer Gooderham, MSc MD FRCPC, Dr Jacob Thyssen, MD PhD DmSci, and Associate Professor Peter Foley, BMedSci MBBS MD FACD, as members of its Scientific Advisory Board (SAB). The SAB, chaired by Dr Lawrence Eichenfield, MD FAAD, was established in September following the appointment of Dr Eichenfield and Dr Eric Simpson, MD MCR. It is comprised of award-winning researchers with global experience in allergic a
MENLO PARK. Calif. and SINGAPORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Dr Lawrence Eichenfield, MD, FAAD, as chair of its Scientific Advisory Board, comprising experts in dermatology and allergic disease from the United States, Canada, Europe, and Asia. Dr Eric Simpson, MD, MCR, was also appointed as a board member. Dr Lawrence Eichenfield is Chief of Pediatric and Adolescent Dermatology at Rady Children's Hospital-San Diego, Distinguished Professor of Dermatology and Pediatrics and Vice C
SINGAPORE, March 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PXS). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of
SINGAPORE, Feb. 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Neil Graham, MBBS, MD, MPH as an independent director. Dr Graham, an expert in immunology and inflammation, has more than 30 years’ experience in global drug development and commercialisation, traversing early and late-stage clinical trials in dermatology, allergy, rheumatology, virology, and pulmonology. Dr Graham is currently Chief Medical Officer of Tiziana Life Sciences plc (Nasdaq:TLSA, AIM:TILS) and a director of Pharmaxis Ltd. Dr Gr
Jefferies initiated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00
HC Wainwright & Co. reiterated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00 from $5.00 previously
Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore) Pte Limited International has been appointed as the official liquidator and will seek potential strategic alternatives for the Company's development programs, eblasakimab and farudodstat SAN MATEO, Calif. and SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals ("ASLAN" or the "Company"), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that its Singapore-incorporated, sole oper
SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that on July 9, 2024, the Company was notified by the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company's non-compliance with the $1.00 bid price and $2.5 million stockholders' equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), respectively, the Staff
SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares ("ADSs") to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares. For the Company's existing ADS holders, the change in the ADS ratio will have the same effect as a one-for-eight reverse ADS split. There will be no change to the C
Translational data presented during a late-breaker poster session from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD indicates that eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrations Results support further investigation of eblasakimab as a potential therapeutic option for COPD with potentially more effective blockade of Type-2 mediated inflammatory effects in lung tissue SAN MATEO, Calif. and SINGAPORE, May 21, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to trans
Positive interim data readout from 22 patients in TREK-DX study of eblasakimab showed unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, versus 14.3% of patients on placebo. On track to report topline data from two Phase 2 studies in the second half of 2024: topline interim data readout from FAST-AA, the Phase 2a, proof-of-concept study of farudodstat in alopecia areata expected in Q3 2024, a
New positive data from an additional analysis of dupilumab-experienced patients treated with eblasakimab 400mg, weekly over 16 weeks further support the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumabData to be presented in a KOL event to be held Tuesday, May 7, 2024 at 8:00 am ET, register here SAN MATEO, Calif. and SINGAPORE, May 07, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, will today host a virtual KOL event, during which Company management will present new data
New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab.The findings will deepen understanding of the biology underlying the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumab.The first part of the collaboration will focus on receptor biology and kinetics to investigate the cellular and molecular basis of eblasakimab's potential for differentiation. This work will be funded by Zenyaku. SAN MATEO, Calif. and SINGAPORE, May 02, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage
ASLAN management will present new data from the interim analysis of the TREK-DX studyRegister here to attend the webinar event on May 7, 2024 at 8:00 AM ET SAN MATEO, Calif. and SINGAPORE, April 30, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host a virtual Key Opinion Leader (KOL) Event, "Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market", to be held on Tuesday, May 7, 2024 from 8:00 AM ET to 9:00 AM
SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease has been accepted for a late breaking poster presentation at the American Thoracic Society International Conference 2024. The conference is taking place in San Diego, California, from May 17 to 22, 2024. American Thoracic Society International Conference poster details Poster title: Eblasakimab Significantly Alleviates IL-4 and IL-13 Induced Bronchial Ai
Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, versus 14.3% of patients on placebo. 20% of patients treated with eblasakimab achieved EASI-100 (100% reduction in their EASI score) versus 0% on placebo.Of the six patients treated with eblasakimab that previously had an inadequate response to dupilumab, 66.7% achieved EASI-90 and a vIGA score of 0 or 1 aft
25-NSE - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)
SCHEDULE 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)
6-K - ASLAN Pharmaceuticals Ltd (0001722926) (Filer)
6-K - ASLAN Pharmaceuticals Ltd (0001722926) (Filer)
EFFECT - ASLAN Pharmaceuticals Ltd (0001722926) (Filer)
6-K - ASLAN Pharmaceuticals Ltd (0001722926) (Filer)
F-6 POS - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)
F-3 - ASLAN Pharmaceuticals Ltd (0001722926) (Filer)
6-K - ASLAN Pharmaceuticals Ltd (0001722926) (Filer)
6-K - ASLAN Pharmaceuticals Ltd (0001722926) (Filer)
- Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile - ASLAN004 achieved a statistically significant improvement (p<0.0251) versus placebo in the primary efficacy endpoint of percent change from baseline in EASI with significant improvements in other efficacy endpoints- Well-tolerated with no cases of conjunctivitis in the expansion cohort- On track to enroll first patient in global Phase 2b study in 4Q 21- Management to host conference call and webcast today, 27 September, at 8am ET / 8pm SGTMENLO PARK, Calif. and SINGAPORE, Sept. 27, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology
SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)
SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)
SC 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)
SC 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)
SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)
SC 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)
SC 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)
SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)
SC 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)
SC 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)